The Development Bank of Wales provides equity and loan financing to support business growth and technological innovation across Wales.
The funding from the Development Bank of Wales supports the construction of 44 new homes in Newtown.
"As a local family-run company, we pride ourselves on building high-quality and good value new homes. Oaks Meadow offers local people the opportunity to buy in their community, be that their place of birth, residency or employment which is why we were keen to make sure that we partnered with a funder who understood the local area."
The funding round was led by the Development Bank of Wales to advance first-in-human studies.
"Vaccination and treatments have reduced the impact of the virus but it is still a significant health risk. Our self-administered and cost-effective antiviral treatment stops the virus from entering and multiplying in the nasal epithelial cells, where it can then spread to the throat and then into the lungs. It is a potential game-changer in the treatment and prevention of coronaviruses, particularly with the emergence of new viruses."
The Swansea-based diagnostics firm secured £1.5m from a syndicate of investors to support product development and clinical trials.
"We’re pleased to have backed CanSense during this investment round with equity support. Their testing technology shows huge potential, with benefits for NHS backlogs if adopted widely, and we’re glad to support the work of this company as it brings its expertise to Wales’ increasingly strong med-tech sector."
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
The funding round was led by business angel Eamon Tuhami alongside Fuel Ventures and matched by the Development Bank of Wales.
"From Pakistan to Dubai then Poland to Cardiff, this has been a three year journey that started in my home garage fondly known as the ‘Gar-Office’."
.png)
